论文部分内容阅读
目的 研究CYP2C19基因多态性与缺血性脑梗死患者服用氯吡格雷的疗效关系.方法 选取79例被诊断为缺血性脑梗死的患者,服用氯吡格雷前行CYP2C19基因型和二磷酸腺苷(ADP)诱导的血小板聚集率等指标检测,服药后1周行ADP诱导的血小板聚集率复测,根据不同的代谢类型对患者进行分组,比较各组患者以上指标的差异.结果 各基因型所占比例:CYP2C19*1/*1为44.30％,CYP2C19* 1/*2为39.24％,CYP2C19* 1/*3为3.80％,CYP2C19* 2/*2为8.86％,CYP2C19* 2/*3为3.80％,CYP2C19*3/*3为0;快代谢型、中间代谢型和慢代谢型之间的ADP诱导血小板聚集率等指标差异无统计学意义.结论 CYP2C19在中国人群中的突变频率较大.本研究的样本量较少,无法得出氯吡格雷疗效与基因型之间的具体关系,还需要增加样本量并综合多因素考虑.“,”AIM To investigate relationship between CYP2C19 gene polymorphisms and effect of clopidogrel in patients with ischemic cerebral infarction.METHODS Totally 79 patients with ischemic cerebral infarction were recruited,and CYP2C19 genotype,adenosine diphosphate (ADP) induced platelet aggregation rate and other indicators before taking clopidogrel were detected.One week after taking clopidogrel ADP-induced platelet aggregation rate were measured again.According to different metabolic types the patients were grouped,the above indicators of each group of patients were compared.RESULTS The CYP2C19 * 1/* 1 was 44.30 ％,CYP2C19 * 1/* 2 was 39.24 ％,CYP2C19 * 1/* 3 was 3.80 ％,CYP2C19 * 2/* 2 was 8.86 ％,CYP2C19 * 2/* 3 was 3.80 ％ and CYP2C19 * 3/* 3 was 0.ADP induced platelet aggregation rate between fast metabolism group,intermediate metabolism group and slow metabolism group and other indicators were not significantly different.CONCLUSION CYP2C19 mutation frequency in the Chinese population is relatively large.Because of the less sample size in this study,clopidogrel effect and the specific relationship between the genotype cannot be obtained,but also need to increase the sample size and comprehensive multi-factor consideration.